CALL ME BACK
Title
First Name
Last Name
Contact Method
-None-
Phone
Phone
Email
Preferred Date
[
4/22/2019
]
Preferred Time (PST)
-None-
5:30 am
5:45 am
6:00 am
6:15 am
6:30 am
6:45 am
7:00 am
7:15 am
7:30 am
7:45 am
8:00 am
8:15 am
8:30 am
8:45 am
9:00 am
9:15 am
9:30 am
9:45 am
10:00 am
10:15 am
10:30 am
10:45 am
11:00 am
11:15 am
11:30 am
11:45 am
12:00 pm
12:15 pm
12:30 pm
12:45 pm
1:00 pm
1:15 pm
1:30 pm
1:45 pm
2:00 pm
2:15 pm
2:30 pm
2:45 pm
3:00 pm
3:15 pm
3:30 pm
3:45 pm
Select a product
-None-
Actemra
Activase
Alecensa
Avastin
Boniva
Cathflo Activase
CellCept
Cotellic
Cytovene
Erivedge
Esbriet
Fuzeon
Gazyva
Hemlibra
Herceptin
Herceptin Hylecta
Invirase
Kadcyla
Klonopin
Lucentis
Nutropin
Ocrevus
Pegasys
Perjeta
Pulmozyme
Rituxan
Rituxan Hycela
Tamiflu
Tarceva
Tecentriq
TNKase
Valcyte
Valium
Venclexta
Xeloda
Xofluza
Xolair
Zelboraf
balovaptan
BALOVAPTAN
CHk1 Inhibitor
crenezumab
entrectinib
etrolizumab
faricimab
gantenerumab
idasanutlin
ipatasertib
lebrikizumab
polatuzumab vedotin
RG6000
RG6029
RG6042
RG6069
RG6100
RG6114/GDC-0077 (PI3K Inhibitor)
RG6171
Other
Other
Actemra
Activase
Alecensa
Avastin
Boniva
Cathflo Activase
CellCept
Cotellic
Cytovene
Erivedge
Esbriet
Fuzeon
Gazyva
Hemlibra
Herceptin
Herceptin Hylecta
Invirase
Kadcyla
Klonopin
Lucentis
Nutropin
Ocrevus
Pegasys
Perjeta
Pulmozyme
Rituxan
Rituxan Hycela
Tamiflu
Tarceva
Tecentriq
TNKase
Valcyte
Valium
Venclexta
Xeloda
Xofluza
Xolair
Zelboraf
balovaptan
BALOVAPTAN
CHk1 Inhibitor
crenezumab
entrectinib
etrolizumab
faricimab
gantenerumab
idasanutlin
ipatasertib
lebrikizumab
polatuzumab vedotin
RG6000
RG6029
RG6042
RG6069
RG6100
RG6114/GDC-0077 (PI3K Inhibitor)
RG6171
-None-
Subject
Company
Question
Are You a Healthcare Professional?
Yes
No
If reporting a product complaint, please call:
Phone: (800) 334-0290
Hours: Monday - Friday, 5am - 5pm PT
Submit
saving...
January
February
March
April
May
June
July
August
September
October
November
December
2018
2019
2020
2021
2022
2023
2024
Sun
Mon
Tue
Wed
Thu
Fri
Sat
Today
